MOMO'S BREAKOUT BOARD

[Vance]

Per the LPCN conference Today:
(Taken from a poster on Yahoo Finance)

1. Commercial partnership discussions are underway and interest has been good. Potential for non-dilutive cash infusion through partnership deal

2. Tlando XR restarts development after Tlando tentative approval. LPCN designing Tlando XR Phase 3 trial

3. They continue to strongly believe that Clarus is infringing on patents, and they hope to prevail with that claim

4. 1144 primary endpoint study to be out in the next few days. Biopsy results to be out in mid 2021. Other data points related to impact on data such as weight, BMI, waist, etc., to be released as the data becomes available prior to mid 2021. Good chance that 1144 will impact these markers

5. If FDA confirms that Makena is out of the market, LPCN 1107 has the potential to become the standard of care.


You can listen via a link from https://ir.lipocine.com/events